Antibody Technologies
Active in antibody development since its foundation in 2001, Glycotope is a specialist for antibody technologies:
During the years, we have developed and improved a large variety of technologies to design, characterize and produce antibodies with optimal product features at highest quality resulting in efficient production conditions:
- Identification and cloning of the hybridoma VL and VH sequences
- Chimerization and humanization
- Protein engineering, especially to modify the site of glycosylation
- Recombinant expression of antibodies in various formats from IgG to IgM
- Transient expression in the liter scale
- Specifically designed expression vectors to achieve high yield production cell clones
- Automated single cell cloning of high yield producers
- Cellular glycoprofiling already at the colony level
- GlycoExpress™ and GlycoOptimization
- Most purification techniques
- Preclinical characterization of antigen binding properties (e.g. ELISA, Biacore, cell binding), biochemical properties including glycosylation and aggregate formation
- In vitro analysis of cellular activities (e.g. ADCC, CDC, phagocytosis)
- Pharmacokinetic and -dynamic studies using radiolabeled antibodies
- Generation of mammalian or human production cell clones under serum free conditions
- Optimization of medium and fermentation conditions with special regard to homogenous glycosylation
